$PHAS PhaseBio Pharmaceuticals Inc Insider Trading
Get free email notifications about insider trading in PhaseBio Pharmaceuticals Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in PhaseBio Pharmaceuticals Inc. Insider overview, share value development, latest insider transactions and email notifications about new events in PhaseBio Pharmaceuticals Inc for free.
IRS Number: 030375697
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Trading Symbol: PHAS
Company Address: 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN 19355
Phone number: (610) 981-6500
Former name: DT BIOSCIENCES INC, date of change: 2002-03-15
Former name: Phase Biosciences Inc, date of change: 2006-10-13
PhaseBio Pharmaceuticals Inc Latest Insider Transactions
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 04 2021 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Option Exercise | A | 3.53 | 14,000 | 49,420 | 14,000 | |
Jun 04 2021 | PHAS | PhaseBio Pharmaceu ... | Loewy Caroline M | Director | Option Exercise | A | 3.53 | 14,000 | 49,420 | 14,000 | |
Jun 04 2021 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | A | 3.53 | 14,000 | 49,420 | 14,000 | |
May 24 2021 | PHAS | PhaseBio Pharmaceu ... | York Michael | VP, Corporate Devel ... | Grant | A | 2.80 | 2,897 | 8,112 | 7,059 | 4.2 K to 7.1 K (+69.61 %) |
May 24 2021 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Grant | A | 2.80 | 5,257 | 14,720 | 23,241 | 18 K to 23.2 K (+29.23 %) |
Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | A | 4.31 | 234,000 | 1,008,540 | 234,000 | |
Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Hanson Kristopher | VP, Head of Legal | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Hanson Kristopher | VP, Head of Legal | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | York Michael | VP, Corporate Devel ... | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | York Michael | VP, Corporate Devel ... | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | Chief Financial Off ... | Option Exercise | A | 4.31 | 76,500 | 329,715 | 76,500 | |
Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | Chief Financial Off ... | Option Exercise | A | 4.31 | 76,500 | 329,715 | 76,500 | |
Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Lee John Sang | Chief Medical Offic ... | Option Exercise | A | 4.31 | 76,500 | 329,715 | 76,500 |